Barclays Downgrades Medivation (MDVN) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Pfizer to Acquire Medivation
August 22, 2016 6:46 AM EDTNEW YORK, NY and SAN FRANCISCO, CA -- (Marketwired) -- 08/22/16 -- Medivation, Inc. (NASDAQ:Â MDVN) -
Propels Pfizer into a leading position in oncologyMedivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billionExpected to be immediately accretive to Pfizer's Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter